Transcript ASCO_GI_2014_files/Allegra R
Neoadjuvant Therapy For Rectal Cancer: Mature Results From NSABP Protocol R-04 A Collaborative National NCI Protocol Conducted by NSABP, NCCTG, ECOG, CALGB, and SWOG CJ Allegra, G Yothers, MJ O’Connell, MS Roh, RW Beart, NJ Petrelli, S Lopa, S Sharif, and N Wolmark
Disclosures •
I have no relevant conflicts of interest to disclose
Goals of NSABP R-04
•
Designed at the start of the millennium to address the questions: –
• • •
Can the oral fluoropyrimidine, capecitabine be substituted for the standard of care in the curative setting of Stage II & III rectal cancer namely, CIV 5-FU, during neoadjuvant RT?
CIV 5-FU became the SoC based on a US cooperative group study (O’Connell et al; NEJM August, 1994) showing superiority over bolus administrations of 5-FU Capecitabine was shown to be non-inferior to 5-FU in the palliative & adjuvant colon settings and does not require a central venous catheter or infusion pump Small retrospective studies support similar outcomes with 5-FU and capecitabine in the rectal neoadjuvant setting – Can the addition of oxaliplatin enhance the activity of fluoropyrimidine sensitized RT?
•
Oxaliplatin was shown to have radiation sensitizing properties in preclinical models
•
Oxaliplatin was shown to enhance the activity of 5-FU in the palliative and adjuvant colon settings
NSABP R-04
•
July, 2004 – 2-arm study comparing 5-FU and Cape ACTIVATION
•
October, 2005 – Added oxaliplatin – – 2 x 2 factorial design AMENDMENT 5-FU and Cape reduced from 7 days/wk to 5 days/wk during RT
•
August, 2010 – CLOSED 1,608 accrued patients; 1595 (99.2%) Eligible
NSABP R-04
Rectal AdenoCa < 12 cm from anal verge STRATIFICATION Gender; Clinical Stage II/III; Intent for Type of Surgery (sphincter saving v. APR) RANDOMIZATION Group 1 5-FU (CIV 225mg/m 2 5d/wk) + RT (46Gy over 5 wks + boost) Group 2 5-FU (CIV 225mg/m 2 5d/wk) + Oxaliplatin 50 mg/m 2 /wk X 5 + RT Group 3 Capecitabine 825 mg/m 2 PO BID + RT Group 4 Capecitabine 825 mg/m 2 PO BID + Oxaliplatin 50 mg/m 2 /wk X 5 + RT
–
NSABP R-04
Primary Endpoint
– •
Local-regional control with 3 years minimum follow-up – –
Time from randomization to first L-R failure Inoperable patients or those with positive margins are considered L-R failures at the time of surgery
–
Patients without documented clinical CR who do not undergo surgery will be considered a L-R failure at the time they should have had surgery •
“Local” – Anastomotic and pelvis
•
“Regional” – Pelvic or retroperitoneal LNs at or below L5
–
NSABP R-04
Secondary Endpoints
–
– – – – – – Rate of pathologic CR Number of pts undergoing sphincter-saving surgery Disease free and overall survival Quality of Life Toxicity Correlating genetic patterns and specific tissue biomarkers with response and prognosis
NSABP R-04
Statistical Design
•
Comparison of cape and 5-FU
Comparable if 0.86 < HazRatio < 1.17
Roughly corresponds to 3yr L-R rate of +/- 2%
•
Superiority for the addition of oxaliplatin to fluoropyrimidines
>80% power for HazRatio = 0.59
Roughly corresponds to 4% increase in L-R 3yr rate
Regimen # Eligible Pts Age (%) ≤ 59 ≥ 60 Gender Male Female Clinical Stage II III SS Surg
Patient Demographics
FU 461 FU+Ox 321 Cape 463 Cape+Ox 322 56 44 67 33 59 41 74 61 39 68 32 62 38 74 56 44 68 32 58 42 73 61 39 68 32 62 38 74 Non-SS Surg 26 26 27 26 Total 1567 60 40 74 26 58 42 68 32
NSABP R-04 pCR Rates (%)
P = 0.14
P = 0.42
* No significant fluoropyrimidine by oxaliplatin interaction
3 Year Overall & L-R Recurrences
P = 0.98
P = 0.70
P = 0.52
P = 0.22
* No significant fluoropyrimidine by oxaliplatin interaction
5 YEAR OUTCOMES (%)
P = 0.70
P = 0.34
P = 0.61
P = 0.38
* No significant fluoropyrimidine by oxaliplatin interaction
NSABP R-04 Primary Endpoint: Local-Regional Control
5-FU vs. Cape No Oxali vs. Oxali 5-FU 782 Pts, 95 L/R Recurrence Cape 785 Pts, 97 L/R Recurrence HR = 1.00, 95% CI (0.75-1.32) P = 0.98
No Oxali 641 Pts, 81 L/R Recurrence Oxali 643 Pts, 76 L/R Recurrence HR = 0.94, 95% CI (0.67-1.29) P = 0.70
0 1 2 3 4 Years from Randomization 5 6 0 1 2 3 4 Years from Randomization 5 6
NSABP R-04 Overall Survival
5-FU vs. Cape No Oxali vs. Oxali 5-FU 782 Pts, 141 deaths Cape 785 Pts, 138 deaths HR = 1.00, 95% CI (0.74-1.19) P = 0.61
No Oxali 641 Pts, 116 deaths Oxali 643 Pts, 103 deaths HR = 0.94, 95% CI (0.68-1.16) P = 0.38
0 1 2 3 4 Years from Randomization 5 6 0 1 2 3 4 Years from Randomization 5 6
Treatment Compliance
•
At least 80% of treatment completed per protocol
– FU – 90% alone; 84% with Oxali – Cap – 97% alone; 96% with Oxali – Oxali – 69% with FU; 62% with Cap – RT – 96-98% depending on the arm
NSABP R-04 Mortality & Adverse Events (%)
Toxicity (Grade) Overall (3+) Diarrhea (3/4) Death (5) 5-FU 26.5
Capecitabine 30.1
5-FU + Oxaliplatin 39.9
Capecitabine + Oxaliplatin 42.2
7 0.3
7 1.3
16 0.3
16 1.6
NSABP R-04 Summary
•
Capecitabine with preop RT achieved rates similar to CIV 5-FU for: – – – – L-R Failure – Primary Endpoint pCR DFS OS
•
Oxaliplatin did not improve outcomes but added significant toxicity (diarrhea) and is therefore not indicated in combination with RT in the preop rectal setting
•
Establishes capecitabine as a standard of care in the preop rectal setting
•
NSABP R-04 supports pCR & neoadjuvant rectal cancer (NAR) score as surrogates for overall survival (Yothers G ASCO GI, 2014; Abst #384)
•
Fully annotated tissue samples available for molecular studies